Antibody-drug conjugates (ADCs) are made up of a monoclonal antibody linked to a cytotoxic drug (payload) through a stable chemical linker, enabling targeted delivery of the drug to specific cancer cells. The ideal ADC payload should have sufficient toxicity, low immunogenicity, high stability, and modifiable functional groups. All approved ADC therapeutics currently possess a single-drug payload, such as monomethyl auristatin E (MMAE), monomethyl auristatin F (MMAF), or maytansinoids like DM1 and DM4. A recent review by Journeaux & Bernardes describes how researchers are now attempting to develop homogenous ADCs with multiple unique payloads to improve the efficacy of targeted therapy. However, due to the many reactive functional groups on the surface of an antibody, this task has been difficult.
DOI: 10.1038/s41557-024-01507-y
Most of the research in this field focuses on dual-payload ADCs. Another review by Wang et al. highlights how dual-payload ADCs can have greater therapeutic effects and survival benefits than just two single-agent combinations. Just a few weeks ago, Hummingbird Bioscience presented promising data on their dual-payload ADC to overcome severe side effects and the intrinsic or acquired resistance seen in patients with earlier generation single payload ADCs.
The problem with heterogeneity within tumors such as breast cancer, is that multiple cells with different gene expression profiles results in drug resistance, recurrence, and metastasis after chemotherapy. Researchers from The University of Texas Health Science Center developed a homogeneous ADC containing two distinct payloads with HER2-specific cell killing potency by chemoenzymatic conjugation. Unlike other methods, their linker systems allowed for the generation of a panel of homogeneous dual-drug ADCs with flexible combined drug-to-antibody ratios (DARs) of 2 + 2, 4 + 2, and 2 + 4. DARs are typically maintained under a value of 4 to avoid monoclonal antibody aggregation and limit hydrophobicity, as they have been linked to toxicity, reduced half-life and a narrow therapeutic index.
Bispecific antibodies are rapidly transforming the therapeutic landscape, especially in oncology and autoimmune diseases. Such recombinant molecules can bind to two different antigens at the same time, offering greater specificity in targeting disease pathways. Since their introduction, the area of bispecifics has held tremendous promise in oncological cancers like multiple myeloma and lymphomas.
A common theme emerging from recent antibody research is the development and validation of advanced diagnostic tools based on antibody detection. Multiple studies highlight the creation of novel biosensors and assays designed to enhance the sensitivity, specificity, and efficiency of detecting antibodies across various diseases.
T cell immunoreceptor with immunoglobulin and ITIM domain (TIGIT) is an immune receptor that plays a key role in suppressing T-cell activation and proliferation. As a newly identified checkpoint, it is highly expressed on various immune cells, including CD4+ and CD8+ T cells, NK cells.
